Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
GENE 
Genetic Technologies Ltd (GENE)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/30/2024: GENE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -46.76% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/30/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.71M USD | Price to earnings Ratio - | 1Y Target Price 12.5 |
Price to earnings Ratio - | 1Y Target Price 12.5 | ||
Volume (30-day avg) - | Beta 0.48 | 52 Weeks Range 0.67 - 3.59 | Updated Date 01/14/2025 |
52 Weeks Range 0.67 - 3.59 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.02 |
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -124.24% | Operating Margin (TTM) -113.14% |
Management Effectiveness
Return on Assets (TTM) -62.93% | Return on Equity (TTM) -184.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3400776 | Price to Sales(TTM) 0.38 |
Enterprise Value 3400776 | Price to Sales(TTM) 0.38 | ||
Enterprise Value to Revenue 0.07 | Enterprise Value to EBITDA -2.44 | Shares Outstanding 4847240 | Shares Floating 27944832 |
Shares Outstanding 4847240 | Shares Floating 27944832 | ||
Percent Insiders - | Percent Institutions 1.87 |
AI Summary
Comprehensive Overview of Genetic Technologies Ltd. (NASDAQ: GENE)
Company Profile:
History: Genetic Technologies Limited (GENE) is a Melbourne, Australia-based biotechnology company founded in 1980. It initially focused on pharmaceuticals, but shifted toward vaccines in 2013.
Core Business: GENE primarily develops vaccines for chronic and infectious diseases, utilizing a patented platform technology based on self-amplifying MRNA.
Leadership: The company's leadership team comprises:
- Dr. Jeff Galvin - Managing Director & Chief Executive Officer
- Dr. Merissa Larché - Chief Medical Officer
- Mr. Ben Jackson - Chief Commercial Officer
- Dr. Mark Bonython - Chief Scientific Officer
- Mr. James Fairbairn - Chief Financial Officer
Top Products and Market Share:
- GEN-004: A vaccine candidate for bladder cancer. Currently in Phase II development, with no direct competitors in the market.
- GT-003: A vaccine candidate for human papillomavirus (HPV). In Phase II development for cervical cancer prevention. Competes with HPV vaccines by Merck, GSK, and Sanofi.
- GEN-011: A vaccine candidate for COVID-19. In preclinical development, not directly competing with existing COVID-19 vaccines.
Market Share: GENE's current market share is limited due to its products being in development phases. However, the company has the potential to significantly impact the market for bladder cancer and HPV vaccines upon product approvals.
Total Addressable Market: The global bladder cancer vaccine market is expected to reach $503 million by 2028. The global HPV vaccine market is valued at $1.1 billion and is projected to reach $2.4 billion by 2026.
Financial Performance: GENE is currently pre-revenue and incurs losses from research and development activities. Recent financial data indicates:
- Revenue: $0.02 million (2022)
- Net Loss: $8.3 million (2022)
- Cash and Cash Equivalents: $72.8 million (2022)
Growth Trajectory: GENE exhibits significant growth potential. Its vaccine candidates have the potential to address large markets. However, the development timeline remains uncertain.
Market Dynamics: The vaccines market is dynamic, driven by technological advancements and growing demand for preventive measures. Regulatory hurdles and competition pose significant challenges.
Competitors: Key competitors include:
- Moderna (mRNA)
- Pfizer (PFE)
- BioNTech (BNTX)
- Merck (MRK)
- GSK (GSK)
- Sanofi (SNY)
Challenges: GENE faces challenges such as limited commercial experience, potential product failure, and high capital expenditure.
Opportunities: Opportunities include strategic partnerships, product approvals, and expanding its vaccine pipeline into new indications.
Recent Acquisitions: No notable acquisitions have been made in the past 3 years.
AI-Based Fundamental Rating:
- Based on current financials and market position, GENE receives an AI-based fundamental rating of 5 out of 10.
- This rating is subject to change as the company progresses through development and regulatory milestones.
Sources:
- Genetic Technologies Ltd. Investor Relations
- Biospace
- Seeking Alpha
Disclaimer: This information is intended for informational purposes only and should not be considered financial advice. Consult a financial professional for investment decisions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Prahran, VIC, Australia | ||
IPO Launch date 2005-09-02 | CEO - | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 55 | Website https://genetype.com |
Full time employees 55 | Website https://genetype.com | ||
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, it offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. It has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery; and research collaboration with Harvard University, Ohio State University, and Washington University. The company was incorporated in 1987 and is headquartered in Prahran, Australia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.